Annual report pursuant to Section 13 and 15(d)

Dispositions (Details)

v3.20.1
Dispositions (Details) - USD ($)
$ in Millions
12 Months Ended
Nov. 04, 2015
Dec. 31, 2018
Asset Purchase Agreement And Ology Bioservices License Agreement    
Dispositions    
Cash consideration   $ 4.6
Amount received from sale of discontinued operation   $ 2.5
Biodefense Business    
Dispositions    
Royalties receivable percentage on net sales 15.00%